Robotic-assisted, laparoscopic, and vaginal hysterectomy in morbidly obese patients with endometrial hyperplasia and endometrial cancer.

IF 1.7 4区医学 Q2 SURGERY

Minimally Invasive Therapy & Allied Technologies Pub Date : 2024-12-01 Epub Date: 2024-09-28 DOI:10.1080/13645706.2024.2407845

Andrea Giannini, Ottavia D'Oria, Enrico Vizza, Mario A Congiu, Ilaria Cuccu, Tullio Golia D'Augè, Stefania Saponara, Giuseppe Capalbo, Violante Di Donato, Francesco Raspagliesi, Giorgio Bogani

{"title":"Robotic-assisted, laparoscopic, and vaginal hysterectomy in morbidly obese patients with endometrial hyperplasia and endometrial cancer.","authors":"Andrea Giannini, Ottavia D'Oria, Enrico Vizza, Mario A Congiu, Ilaria Cuccu, Tullio Golia D'Augè, Stefania Saponara, Giuseppe Capalbo, Violante Di Donato, Francesco Raspagliesi, Giorgio Bogani","doi":"10.1080/13645706.2024.2407845","DOIUrl":null,"url":null,"abstract":"Background: Hysterectomy for endometrial hyperplasia and endometrial cancer in morbidly obese patients is challenging. Here, we reported data regarding three minimally invasive approaches.Method: This is a multicenter retrospective study evaluating 30-day and 90-day surgery-related outcomes of morbidly obese patients (those with BMI > 40kg/m2) undergoing robotic-assisted, laparoscopic, and vaginal hysterectomy.Results: Charts of 95 morbidly obese patients who underwent surgery for endometrial cancer were retrieved. Overall, robotic-assisted, laparoscopic, and vaginal surgeries were performed in 35 (36.8%), 38 (40%), and 22 (23.2%) patients, respectively. Patients having robotic-assisted surgery experienced longer operative time than patients having vaginal and laparoscopic approaches (p < 0.001). Surgical approaches did not influence the risk of having intraoperative and severe (Clavien-Dindo grade 3 or more) postoperative complications. No 90-day mortality occurred.Conclusions: Robotic-assisted, laparoscopic, and vaginal surgery represent three safe and feasible minimally invasive approaches to manage morbidly obese patients with endometrial hyperplasia and endometrial cancer.","PeriodicalId":18537,"journal":{"name":"Minimally Invasive Therapy & Allied Technologies","volume":" ","pages":"358-364"},"PeriodicalIF":1.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minimally Invasive Therapy & Allied Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13645706.2024.2407845","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hysterectomy for endometrial hyperplasia and endometrial cancer in morbidly obese patients is challenging. Here, we reported data regarding three minimally invasive approaches.

Method: This is a multicenter retrospective study evaluating 30-day and 90-day surgery-related outcomes of morbidly obese patients (those with BMI > 40kg/m²) undergoing robotic-assisted, laparoscopic, and vaginal hysterectomy.

Results: Charts of 95 morbidly obese patients who underwent surgery for endometrial cancer were retrieved. Overall, robotic-assisted, laparoscopic, and vaginal surgeries were performed in 35 (36.8%), 38 (40%), and 22 (23.2%) patients, respectively. Patients having robotic-assisted surgery experienced longer operative time than patients having vaginal and laparoscopic approaches (p < 0.001). Surgical approaches did not influence the risk of having intraoperative and severe (Clavien-Dindo grade 3 or more) postoperative complications. No 90-day mortality occurred.

Conclusions: Robotic-assisted, laparoscopic, and vaginal surgery represent three safe and feasible minimally invasive approaches to manage morbidly obese patients with endometrial hyperplasia and endometrial cancer.

查看原文本刊更多论文

对患有子宫内膜增生症和子宫内膜癌的病态肥胖患者进行机器人辅助、腹腔镜和阴道子宫切除术。

背景：对病态肥胖患者进行子宫内膜增生和子宫内膜癌切除术具有挑战性。在此，我们报告了三种微创方法的相关数据：这是一项多中心回顾性研究，评估了接受机器人辅助、腹腔镜和阴道子宫切除术的病态肥胖患者（体重指数大于 40kg/m2）的 30 天和 90 天手术相关结果：检索了95名接受子宫内膜癌手术的病态肥胖患者的病历。总体而言，分别有35名（36.8%）、38名（40%）和22名（23.2%）患者接受了机器人辅助、腹腔镜和阴道手术。与阴道镜和腹腔镜手术相比，机器人辅助手术患者的手术时间更长（P机器人辅助手术、腹腔镜手术和阴道手术是治疗病态肥胖的子宫内膜增生症和子宫内膜癌患者的三种安全可行的微创方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minimally Invasive Therapy & Allied Technologies 医学-外科

CiteScore

3.80

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Minimally Invasive Therapy and Allied Technologies (MITAT) is an international forum for endoscopic surgeons, interventional radiologists and industrial instrument manufacturers. It is the official journal of the Society for Medical Innovation and Technology (SMIT) whose membership includes representatives from a broad spectrum of medical specialities, instrument manufacturing and research. The journal brings the latest developments and innovations in minimally invasive therapy to its readers. What makes Minimally Invasive Therapy and Allied Technologies unique is that we publish one or two special issues each year, which are devoted to a specific theme. Key topics covered by the journal include: interventional radiology, endoscopic surgery, imaging technology, manipulators and robotics for surgery and education and training for MIS.